Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology; Combination Drug Shows Promise


Data demonstrates halting of disease progression in patients with amyotrophic lateral sclerosis (ALS) (Lou Gehrig’s disease) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced regulatory T cell (Treg) number and suppressive function in patients who were administered a combination of CTLA4-Ig fusion protein (CTLA4-Ig) and low dose interleukin-2 (LD IL-2). Prior to initiating treatment, patients were declining at an average rate of -1.1 points per month on the ALSFRS-R rating scale- At the end of 6 months of treatment, the mean rate of change on the ALSFRS-R was +0.04 points per month.
Disease progression remained relatively unchanged during the first 6 months of CTLA4-Ig/LD IL-2 treatment.

Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, has announced the June 9, 2024 publication of a peer-reviewed manuscript titled, “A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,” in the medical journal Frontiers in Neurology. The open-access article can be viewed here.

Login Or Register To Read Full Story